Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 21, 2014; 20(35): 12574-12580
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12574
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12574
Table 1 Patient characteristics
Patient characteristics | n (%) |
Age at diagnosis (yr) | 262 (34) |
Gender | |
Male | 127 (48.5) |
Female | 135 (51.5) |
Extent of the disease | |
Proctitis | 43 (16.4) |
Proctosigmoiditis | 47 (17.9) |
Left-sided colitis | 50 (19.1) |
Pancolitis | 114 (43.5) |
Unknown | 8 (3.0) |
Extraintestinal manifestations | |
Eyes | 2 (0.8) |
Skin | 6 (2.3) |
Joints | 50 (19.1) |
Immunosuppressive therapy | |
Azathioprine | 98 (94.2) |
6-Mercaptopurine | 23 (22.1) |
Infliximab | 36 (34.6) |
Adalimumab | 3 (2.9) |
Golimumab | 1 (1.0) |
Methotrexate | 3 (2.9) |
Miscellaneous | 12 (11.5) |
Reason for IT | |
Steroid-refractory disease course | 40 (38.4) |
Chronic-active disease course | 31 (29.8) |
Steroid-dependent disease course | 27 (26.0) |
Miscellaneous | 6 (5.8) |
Table 2 Independent parameters associated with a severe course of ulcerative colitis, predicting the risk for subsequent necessity of immunosuppressive therapy (multivariate analysis)
Parameter | OR | 95%CI | P value |
Age at diagnosis | 0.981 (per year) | 0.967-0.995 | 0.009 |
Gender (female) | 1.3 | 0.9-2.0 | 0.156 |
Steroid therapy at diagnosis | 2.4 | 1.6-3.7 | < 0.001 |
Hospitalisation at diagnosis | 2.5 | 1.5-4 | < 0.001 |
Extent of the disease | < 0.001 | ||
Proctitis | 1 | ||
Procto-sigmoiditis | 3.5 | 1.4-8.6 | 0.007 |
Left-sided colitis | 5.3 | 1.6-15.3 | 0.002 |
Pancolitis | 6.1 | 2.1-17.5 | 0.001 |
Result of steroid therapy | < 0.001 | ||
No steroids | 1 | ||
Remission | 5.2 | 1.4-20.3 | 0.016 |
Response | 15.3 | 4.7-50 | < 0.001 |
Steroid-dependent | 50.8 | 15.2-170 | < 0.001 |
Steroid-refractory | 34.8 | 10.5-114.8 | < 0.001 |
- Citation: Stallmach A, Nickel L, Lehmann T, Bokemeyer B, Bürger M, Hüppe D, Kruis W, Nikolaus S, Preiss JC, Sturm A, Teich N, Schmidt C. Parameters of a severe disease course in ulcerative colitis. World J Gastroenterol 2014; 20(35): 12574-12580
- URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12574.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i35.12574